SEC Form 4 · accession 0001358403-15-000020
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
David M. Spencer
Officer — Chief Scientific Officer
Period of report
Jun 16, 2015
Accepted (ET)
Jun 18, 2015 · 5:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 16, 2015 | S | 17,200 | $22.8227 | D | 165,554 | D | |
| Common StockF3 | Jun 16, 2015 | S | 2,800 | $23.7939 | D | 162,754 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 23, 2015.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.52 to $23.51. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.52 to $24.07. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.